Category: Parkinson’s Disease: Clinical Trials
Objective: To assess the impact of foscarbidopa/foslevodopa (CDp/LDp) continuous subcutaneous infusion (CSCI) on longest consecutive duration of Good and Best ON time and association of motor predictability with quality of life (QoL) in people with Parkinson’s disease (PD).
Background: CDp/LDp CSCI has shown significant improvements in mean daily ON time without troublesome dyskinesia (Good ON time) in a randomized, double-blind, active-controlled, 12-week phase 3 trial (NCT04380142)[1]; a single-arm, open-label, 52-week trial (NCT03781167)[2]; and sustained response in a 96-week open-label extension (NCT04750226)[3] of the 12-week trial.
Method: Longest consecutive duration of Good and Best ON time (ON time without dyskinesia) from PD Hauser Diaries were analyzed post hoc from the active-controlled trial or from CDp/LDp-treated patients pooled across the 3 trials above. Significance was assessed via one-sample and two-sided paired-sample t-tests, or ANCOVA. Increased motor predictability was defined as improvement from baseline of 1 hour (6% of waking day) or more in matching motor states over 3 days. QoL measured via PDQ-39 Summary Index (PDQ-39-SI) in patients grouped by increased (≥6%)/not increased (<6%) motor predictability were analyzed via Wilcoxon Signed-Rank test. Logistic regression modeled probability of achieving PDQ-39-SI MCID (≤ -4.72)[4].
Results: Longest consecutive duration of Good and Best ON time in CDp/LDp-treated patients was significantly increased from baseline within active-controlled and pooled trial groups, and was significantly improved in CDp/LDp- vs oral-treated active-controlled trial patients by >3 hours [figure1][figure2]. CDp/LDp-treated patients with increased motor predictability from the active-controlled (n=24; odds ratio [OR] 1.80) and pooled (n=87; OR 1.53) trials as well as pooled patients with no increased motor predictability both had correlating improvements in PDQ-39-SI, and improvements in PDQ-39-SI were numerically greater in the CDp-LDp-treated patients with increased motor predictability.
Conclusion: CDp/LDp significantly increased the longest consecutive Good and Best ON time and provided improved ON durations compared to oral treatment. Increased motor predictability in CDp/LDp-treated patients was correlated with clinically meaningful QoL (PDQ-39-SI) improvements, although this was not statistically significant.
Figure 1
Figure 2
References: [1] Soileau MJ, et al. Lancet Neuro. 2022;21:1099-1109.
[2] Aldred J, et al. Neurol Ther. 2023;12(6):1937-1958.
[3] Hauser R, et al. Mov Disord. 2024;39(Suppl 1; Abstract 693):S317-318.
[4] Horváth K, et al. Neuroepidemiology. 2017;48(1-2):1-8.
To cite this abstract in AMA style:
M. Bouchard, R. Hauser, P. Odin, D. Kern, S. Isaacson, L. Bergmann, L. Harmer, J. Homola, R. Gupta, C. Yan, C. Carroll. Foscarbidopa/Foslevodopa Therapy Improves Continuous Duration of Good ON Time and Correlated With Quality of Life in People With Parkinson’s Disease [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/foscarbidopa-foslevodopa-therapy-improves-continuous-duration-of-good-on-time-and-correlated-with-quality-of-life-in-people-with-parkinsons-disease/. Accessed November 20, 2025.« Back to 2025 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/foscarbidopa-foslevodopa-therapy-improves-continuous-duration-of-good-on-time-and-correlated-with-quality-of-life-in-people-with-parkinsons-disease/